Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2022 ,inter alia, to consider and approve 1. A meeting of the Board of Directors will be held on Wednesday, 25-May-22, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-22. 2. In the above meeting, the Board would also consider the following: i. Recommendation of final dividend, if any, on the equity shares of the Company, for the year 2021-22. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders'' approval in the ensuing Annual General Meeting.
06-05-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Credit Rating

 Intimation of Credit rating
28-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Partial Redemption Of Non-Convertible Debentures

 Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that the Secured Redeemable Non-Convertible Debentures (NCDs) of Rs 25 crores (Rupees Twenty Five Crores) out of the total NCDs of Rs 195 crores (Rupees One Hundred Ninety Five Crores) issued under ISIN: INE685A07108 has been * redeemed and repaid by the Company on 22-Apr-22.
22-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Compay TORRENT PHARMACEUTICALS LTD. 2 CIN L24230GJ1972PLC002126 3 Report filed for FY 2021-22 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 0 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 0 6 Actual borrowings done through debt securities in FY(c) 0 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} 0 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities NA Name of the Company Secretary :-Mahesh AgrawalDesignation :-VP Legal and Company Secretary Name of the Chief Financial Officer :- Sudhir Menon Designation : -Chief Financial Officer Date: 16/04/2022
16-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate

 Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayTORRENT PHARMACEUTICALS LTD. 2CINL24230GJ1972PLC002126 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 2943.00 4Highest Credit Rating during the previous FY AA 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Mahesh Agrawal Designation: VP Legal Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Sudhir Menon Designation: Chief Financial Officer EmailId: [email protected] Date: 16/04/2022 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.
16-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Year Ended On 31St March, 2022

 In compliance with the requirements under 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, kindly find enclosed herewith Compliance Certificate for year ended on 31st March, 2022.
12-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Compliance Certificate Under Regulation 40(9) Of The SEBI (LODR) Regulations, 2015

 With reference to the above, we send herewith a copy of the Compliance Certificate under Regulation 40(9) of the SEBI (LODR) Regulations, 2015 issued by RPAP & Co., Practicing Company Secretaries, Ahmedabad in respect of transfer of securities of the Company during the year ended on 31st March, 2022.
12-04-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Closure of Trading Window

 Pursuant to Code of Conduct to Regulate, Monitor and Report Trading by Designated Persons of the Company (''Code'') and applicable SEBI Regulations, we would like to inform you that trading window for dealing in securities of the Company by Designated Persons stands closed from 1st April, 2022 and will be re-opened 48 hours after the submission of the Audited Financial Results for the Financial Year ended 31st March, 2022 to the Stock Exchanges.
25-03-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Torrent Pharma enters into licensing agreement with Medicine Patent Pool to manufacture and commercialise generic version of Pfizer Oral COVID-19 Treatment
17-03-2022
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Name Change Of Registrar & Share Transfer Agent From "KFIN TECHNOLOGIES PRIVATE LIMITED" To "KFIN TECHNOLOGIES LIMITED"

 The Company has been informed that the name of Registrar & Share Transfer Agent (RTA) has been changed from KFIN TECHNOLOGIES PRIVATE LIMITED to KFIN TECHNOLOGIES LIMITED pursuant to conversion of its status from private limited company to public limited company. We request you to take note of the same and update the name of "KFIN TECHNOLOGIES LIMITED" as the RTA of the Company in your records.
16-03-2022
Next Page
Close

Let's Open Free Demat Account